The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Biomea Fusion, Inc. is $7.00, about 469.1% above its August 4 closing price of $1.23.
Quarterly results
Biomea Fusion, the US diabetes and obesity drug developer, said its second-quarter net loss narrowed from a year earlier.
The company reported a second-quarter net loss of $8.30 million, or $0.12 per basic share.
Lower research and development expenses and lower general and administrative expenses drove the reduced loss.
Outlook and cash runway
Biomea Fusion expects initial obesity trial data in .
BMEA•
